PL2994126T3 - Combination of a pi3 kinase inhibitor with paclitaxel for use in the treatment or prevention of a cancer of the head and neck - Google Patents

Combination of a pi3 kinase inhibitor with paclitaxel for use in the treatment or prevention of a cancer of the head and neck

Info

Publication number
PL2994126T3
PL2994126T3 PL14731782T PL14731782T PL2994126T3 PL 2994126 T3 PL2994126 T3 PL 2994126T3 PL 14731782 T PL14731782 T PL 14731782T PL 14731782 T PL14731782 T PL 14731782T PL 2994126 T3 PL2994126 T3 PL 2994126T3
Authority
PL
Poland
Prior art keywords
paclitaxel
cancer
neck
prevention
head
Prior art date
Application number
PL14731782T
Other languages
Polish (pl)
Inventor
Samit Hirawat
Cristian MASSACESI
Emmanuelle DI TOMASO
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL2994126T3 publication Critical patent/PL2994126T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dermatology (AREA)
PL14731782T 2013-05-07 2014-05-06 Combination of a pi3 kinase inhibitor with paclitaxel for use in the treatment or prevention of a cancer of the head and neck PL2994126T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1354211 2013-05-07
PCT/IB2014/061239 WO2014181252A1 (en) 2013-05-07 2014-05-06 Combination of a pi3 kinase inhibitor with paclitaxel for use in the treatment or prevention of a cancer of the head and neck
EP14731782.0A EP2994126B1 (en) 2013-05-07 2014-05-06 Combination of a pi3 kinase inhibitor with paclitaxel for use in the treatment or prevention of a cancer of the head and neck

Publications (1)

Publication Number Publication Date
PL2994126T3 true PL2994126T3 (en) 2018-11-30

Family

ID=49620017

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14731782T PL2994126T3 (en) 2013-05-07 2014-05-06 Combination of a pi3 kinase inhibitor with paclitaxel for use in the treatment or prevention of a cancer of the head and neck

Country Status (20)

Country Link
US (2) US20160082012A1 (en)
EP (1) EP2994126B1 (en)
JP (2) JP6643978B2 (en)
KR (1) KR102356393B1 (en)
CN (1) CN105228611B (en)
AU (1) AU2014264318B2 (en)
BR (1) BR112015027047A2 (en)
CA (1) CA2909448C (en)
CY (1) CY1120693T1 (en)
DK (1) DK2994126T3 (en)
ES (1) ES2688464T3 (en)
HR (1) HRP20181489T1 (en)
HU (1) HUE039393T2 (en)
LT (1) LT2994126T (en)
MX (1) MX2015015475A (en)
PL (1) PL2994126T3 (en)
PT (1) PT2994126T (en)
RU (1) RU2672555C2 (en)
SI (1) SI2994126T1 (en)
WO (1) WO2014181252A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي PI-3 Kinase inhibitors and methods of their use
WO2009155659A1 (en) * 2008-06-27 2009-12-30 The University Of Queensland Combination therapy
WO2012118978A1 (en) * 2011-03-03 2012-09-07 The Regents Of The University Of Colorado, A Body Corporate Methods for treating oncovirus positive cancers

Also Published As

Publication number Publication date
JP2016518400A (en) 2016-06-23
DK2994126T3 (en) 2018-09-24
ES2688464T3 (en) 2018-11-02
BR112015027047A2 (en) 2017-07-25
CA2909448C (en) 2021-10-26
CN105228611B (en) 2018-01-26
HRP20181489T1 (en) 2018-11-16
WO2014181252A1 (en) 2014-11-13
AU2014264318A1 (en) 2015-10-22
CY1120693T1 (en) 2019-12-11
US20160082012A1 (en) 2016-03-24
LT2994126T (en) 2018-09-25
JP6643978B2 (en) 2020-02-12
US20170173032A1 (en) 2017-06-22
PT2994126T (en) 2018-10-22
HUE039393T2 (en) 2018-12-28
RU2015152032A (en) 2017-06-13
EP2994126B1 (en) 2018-06-20
AU2014264318B2 (en) 2017-03-16
RU2672555C2 (en) 2018-11-16
MX2015015475A (en) 2016-03-21
JP2019131559A (en) 2019-08-08
SI2994126T1 (en) 2018-10-30
CA2909448A1 (en) 2014-11-13
EP2994126A1 (en) 2016-03-16
KR20160005702A (en) 2016-01-15
US9913846B2 (en) 2018-03-13
KR102356393B1 (en) 2022-01-26
CN105228611A (en) 2016-01-06

Similar Documents

Publication Publication Date Title
IL304851A (en) Tazemetostat in combination with a standard care agent for use in the treatment of cancer
GB2513167B (en) Tetrahydrocannabivarin for use in the treatment of nausea and vomiting
PL3091008T3 (en) Kinase inhibitor and use thereof
HUE070659T2 (en) A kdm1a inhibitor and its use in therapy
PT3004108T (en) Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease
SG11201604795RA (en) Bicyclic heterocycle compounds and their uses in therapy
SG11201509555UA (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
IL242021B (en) Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
HUE052930T2 (en) Use of dnq or dnq-87 in combination with a parp1 inhibitor for the treatment of cancer
IL267238A (en) Heparanase inhibitors and use thereof
GB201604213D0 (en) Drug combination and its use in therapy
LT3057589T (en) (s)-pirlindole and its pharmaceutically acceptable salts for use in medicine
IL248854A0 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
IL245998B (en) Pharmaceutical compositions for use in the treatment and prevention of metastatic cancer
ZA201600312B (en) Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders
IL267243A (en) Heparanase inhibitors and use thereof
IL251407A0 (en) Multivalent compounds for use in the treatment and prevention of brain damage
HUE039393T2 (en) Combination of a pi3 kinase inhibitor with paclitaxel for use in the treatment or prevention of a cancer of the head and neck
HUE047636T2 (en) Arginine for use in the treatment and/or prevention of osteoarthritis
ZA201600894B (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the prevention and treatment of diabetes
GB201312131D0 (en) Drug combination and its use in therapy
GB201312128D0 (en) Drug combination and its use in therapy
GB201312129D0 (en) Drug combination and its use in therapy